- Home
- GERN vs CINT Comparison
GERN vs CINT Comparison
Compare GERN & CINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- CINT
- Stock Information
- Founded
- GERN 1990
- CINT 1995
- Country
- GERN United States
- CINT Brazil
- Employees
- GERN N/A
- CINT N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- CINT EDP Services
- Sector
- GERN Health Care
- CINT Technology
- Exchange
- GERN Nasdaq
- CINT Nasdaq
- Market Cap
- GERN 878.9M
- CINT 833.8M
- IPO Year
- GERN 1996
- CINT 2021
- Fundamental
- Price
- GERN $1.27
- CINT $5.02
- Analyst Decision
- GERN Buy
- CINT Buy
- Analyst Count
- GERN 11
- CINT 6
- Target Price
- GERN $5.80
- CINT $7.72
- AVG Volume (30 Days)
- GERN 15.1M
- CINT 112.7K
- Earning Date
- GERN 05-07-2025
- CINT 05-21-2025
- Dividend Yield
- GERN N/A
- CINT N/A
- EPS Growth
- GERN N/A
- CINT 14.74
- EPS
- GERN N/A
- CINT 0.22
- Revenue
- GERN $76,994,000.00
- CINT $438,961,000.00
- Revenue This Year
- GERN $208.83
- CINT $537.19
- Revenue Next Year
- GERN $57.49
- CINT $14.48
- P/E Ratio
- GERN N/A
- CINT $23.03
- Revenue Growth
- GERN 32386.92
- CINT N/A
- 52 Week Low
- GERN $1.19
- CINT $3.34
- 52 Week High
- GERN $5.34
- CINT $8.04
- Technical
- Relative Strength Index (RSI)
- GERN 34.43
- CINT 35.17
- Support Level
- GERN $1.17
- CINT $4.81
- Resistance Level
- GERN $1.39
- CINT $5.31
- Average True Range (ATR)
- GERN 0.13
- CINT 0.30
- MACD
- GERN 0.01
- CINT -0.00
- Stochastic Oscillator
- GERN 21.74
- CINT 36.36
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About CINT CI&T Inc
CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.